DiaMedica Therapeutics Inc. (DMAC): Price and Financial Metrics
GET POWR RATINGS... FREE!
DMAC Stock Price Chart Interactive Chart >
DMAC Price/Volume Stats
| Current price | $1.32 | 52-week high | $3.23 |
| Prev. close | $1.35 | 52-week low | $1.12 |
| Day low | $1.30 | Volume | 38,570 |
| Day high | $1.33 | Avg. volume | 38,308 |
| 50-day MA | $1.46 | Dividend yield | N/A |
| 200-day MA | $1.67 | Market Cap | 34.90M |
DiaMedica Therapeutics Inc. (DMAC) Company Bio
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Latest DMAC News From Around the Web
Below are the latest news stories about DIAMEDICA THERAPEUTICS INC that investors may wish to consider to help them evaluate DMAC as an investment opportunity.
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Insider Buying: The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Independent Director Just Bought 38% More SharesWhilst it may not be a huge deal, we thought it was good to see that the DiaMedica Therapeutics Inc. ( NASDAQ:DMAC... |
$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are BuyingThe Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. DiaMedica Therapeutics The Trade: DiaMedica Therapeutics Inc. (NASDAQ: DMAC ) Director Michael Randall Giuffre bought a total of 67,228 … Full story available on Benzinga.com |
DiaMedica Therapeutics (DMAC) Investor Presentation - Slideshow (NASDAQ:DMAC)The following slide deck was published by DiaMedica Therapeutics Inc. |
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial ResultsDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorde |
DMAC Price Returns
| 1-mo | -8.97% |
| 3-mo | 6.45% |
| 6-mo | -23.70% |
| 1-year | -52.35% |
| 3-year | -71.91% |
| 5-year | N/A |
| YTD | -16.46% |
| 2022 | -57.64% |
| 2021 | -63.21% |
| 2020 | 109.07% |
| 2019 | 66.67% |
| 2018 | N/A |
Loading social stream, please wait...